SCHEMBL29569672

SCHEMBL29569672

O=c1ccc(-c2ccc(OC(F)F)cc2)nn1Cc1nc2ccccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ PKM P14618 1/20 0.43
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ IRAK4 Q9NWZ3 5/20 0.40
▸ IRAK1 P51617 3/20 0.40
▸ DRD4 P21917 2/20 0.40
▸ HPGD P15428 1/20 0.39
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23528410 1.00 SMN1; SMN2 (0.46) SMN1; SMN2LMNAKDM4ENPC1RAB9A
SCHEMBL23528455 0.80 MEN1 (0.46) SMN1; SMN2KDM4EMEN1KMT2ATP53
SCHEMBL23528360 0.79 MAPT (0.44) SMN1; SMN2KDM4EMEN1KMT2ATP53
SCHEMBL23528583 0.78 MEN1 (0.46) SMN1; SMN2KDM4EMEN1KMT2ATP53
SCHEMBL23528355 0.78 MET (0.46) SMN1; SMN2KDM4EMEN1KMT2ATP53
SCHEMBL23528332 0.78 KMT2A (0.42) SMN1; SMN2KDM4ENPC1RAB9AMEN1
SCHEMBL29569504 0.78 KMT2A (0.42) SMN1; SMN2KDM4ENPC1RAB9AMEN1
SCHEMBL23528407 0.78 MAT2A (0.39) SMN1; SMN2KDM4EMEN1KMT2ATP53
SCHEMBL23528431 0.77 MEN1 (0.39) SMN1; SMN2KDM4EMEN1KMT2ATP53
SCHEMBL26531415 0.76 MEN1 (0.38) SMN1; SMN2KDM4EMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223278-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-07-10 — — US disclosed
US-12240831-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-03-04 — — US disclosed
US-12012395-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2024-06-18 — — US disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 — — US disclosed
EP-4248973-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 — — EP disclosed
US-20220106291-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2022-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012395-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A SMN1; SMN2 9/4885LMNA 439/4885KDM4E 3514/4885
US-12240831-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A SMN1; SMN2 9/4885LMNA 439/4885KDM4E 3514/4885
US-20220106291-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A SMN1; SMN2 9/4885LMNA 439/4885KDM4E 3514/4885
US-20250223278-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A SMN1; SMN2 9/4885LMNA 439/4885KDM4E 3514/4885
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A SMN1; SMN2 9/4885LMNA 439/4885KDM4E 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback